Renal toxicity of targeted therapies

Targeted Oncology

Volumn 4, Issue 2, 2009, Pages 121-133

  Kelly, Ronan J ^a   Billemont, Bertrand ^b   Rixe, Olivier ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Cochin Hospital ^*  (France)

Author keywords

Bevacizumab; Renal toxicity; Sorafenib; Sunitinib; Targeted therapies

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EZN 2968; FLUOROURACIL; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON; LAPATINIB; NILOTINIB; NOTCH RECEPTOR; OXALIPLATIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ACNE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; DIARRHEA; DRUG TARGETING; DRY SKIN; ENDOTHELIUM CELL; FATIGUE; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; KNOCKOUT MOUSE; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR TARGETED THERAPY; MOUSE; NAUSEA; NEPHRON; NEPHROTOXICITY; NONHUMAN; OVARY CANCER; PLEIOTROPY; PODOCYTE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEINURIA; RASH; REVIEW; SQUAMOUS CELL CARCINOMA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING;

ANTIBODIES, MONOCLONAL; BENZENESULFONATES; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPERTENSION; INDOLES; KIDNEY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PROTEINURIA; PYRIDINES; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67349123313     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-009-0109-x     Document Type: Review

References (100)

1. HF Dvorak 2002 Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy Clin Oncol 20 21 4368 4380 (Pubitemid 35266299)
2. LM Ellis DJ Hicklin 2008 Pathways mediating resistance to vascular endothelial growth factor-targeted therapy Clin Cancer Res 14 20 6371 6375
3. PM Lorusso JP Eder 2008 Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology Expert Opin Investig Drugs 17 7 1013 1028
4. E Raymond S Faivre JP Armand 2000 Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy Drugs 60 Suppl 1 15 23
5. J Li T Hampton JP Morgan M Simons 1997 Stretch-induced VEGF expression in the heart J Clin Invest 100 1 18 24 (Pubitemid 27311238)
6. AS Maharaj M Saint-Geniez AE Maldonado PA D'Amore 2006 Vascular endothelial growth factor localization in the adult Am J Pathol 168 2 639 648 (Pubitemid 43271161)
7. AS Maharaj PA D'Amore 2007 Roles for VEGF in the adult Microvasc Res 74 2-3 100 113 (Pubitemid 350051021)
8. T Couffinhal M Kearney B Witzenbichler D Chen T Murohara DW Losordo J Symes JM Isner 1997 Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries Am J Pathol 150 5 1673 1685 (Pubitemid 27193815)
9. I Stalmans YS Ng R Rohan M Fruttiger A Bouché A Yuce H Fujisawa B Hermans M Shani S Jansen D Hicklin DJ Anderson T Gardiner HP Hammes L Moons M Dewerchin D Collen P Carmeliet PA D'Amore 2002 Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms J Clin Invest 109 3 327 336 (Pubitemid 34141806)
10. WT Monacci MJ Merrill EH Oldfield 1993 Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues Am J Physiol 264 4 Pt 1 C995 C1002
11. U Kilic E Kilic A Järve Z Guo A Spudich K Bieber U Barzena CL Bassetti HH Marti DM Hermann 2006 Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways J Neurosci 26 48 12439 12446 (Pubitemid 44864508)
12. DR Senger SJ Galli AM Dvorak CA Perruzzi VS Harvey HF Dvorak 1983 Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science. 219 4587 983 985
13. I Krämer HP Lipp 2007 Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer J Clin Pharm Ther 32 1 1 14 (Pubitemid 46213936)
14. LG Presta H Chen SJ O'Connor V Chisholm YG Meng L Krummen M Winkler N Ferrara 1997 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 20 4593 4599 (Pubitemid 27441066)
15. DV Tassev NK Cheung 2009 Monoclonal antibody therapies for solid tumors Expert Opin Biol Ther 9 3 341 353
16. N Ferrara KJ Hillan HP Gerber W Novotny 2004 Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 5 391 400 (Pubitemid 38618122)
17. HF Dvorak 2002 Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J Clin Oncol 20 21 4368 4380 (Pubitemid 35266299)
18. MS Gordon K Margolin M Talpaz GW Sledge Jr E Holmgren R Benjamin S Stalter S Shak D Adelman 2001 Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 3 843 850 (Pubitemid 32119100)
19. C Frangié C Lefaucheur J Medioni C Jacquot GS Hill D Nochy 2007 Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma Lancet Oncol 8 2 177 178 (Pubitemid 46158384)
20. D Roncone A Satoskar T Nadasdy JP Monk BH Rovin 2007 Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma Nat Clin Pract Nephrol 3 5 287 293 (Pubitemid 46674523)
21. X Zhu S Wu WL Dahut CR Parikh 2007 Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis Am J Kidney Dis 49 2 186 193 (Pubitemid 46178407)
22. V Eremina HJ Baelde SE Quaggin 2007 Role of the VEGF-a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier Nephron Physiol 106 2 32 37
23. V Eremina JA Jefferson J Kowalewska H Hochster M Haas J Weisstuch C Richardson JB Kopp MG Kabir PH Backx HP Gerber N Ferrara L Barisoni CE Alpers SE Quaggin 2008 VEGF inhibition and renal thrombotic microangiopathy N Engl J Med 358 11 1129 1136
24. RJ Levine C Lam C Qian KF Yu SE Maynard BP Sachs BM Sibai FH Epstein R Romero R Thadhani SA Karumanchi 2006 CPEP study group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia N Engl J Med 355 10 992 1005 (Pubitemid 44343543)
25. BA George XJ Zhou R Toto 2007 Nephrotic syndrome after bevacizumab: case report and literature review Am J Kidney Dis 49 2 e23 e29
26. MR Hoenig C Bianchi A Rosenzweig FW Sellke 2008 The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure Curr Vasc Pharmacol 6 4 292 300
27. H Izzedine B Billemont F Thibault O Rixe 2007 New challenges in kidney cancer therapy: sunitinib Ann Oncol 18 Suppl 9 ix83 ix86
28. S Faivre C Delbaldo K Vera C Robert S Lozahic N Lassau C Bello S Deprimo N Brega G Massimini JP Armand P Scigalla E Raymond 2006 Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 1 25 35 (Pubitemid 46630490)
29. RJ Motzer TE Hutson P Tomczak MD Michaelson RM Bukowski O Rixe S Oudard S Negrier C Szczylik ST Kim I Chen PW Bycott CM Baum RA Figlin 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2 115 124 (Pubitemid 46089672)
30. G Bollée N Patey G Cazajous C Robert JM Goujon F Fakhouri P Bruneval LH Noël B Knebelmann 2009 Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib Nephrol Dial Transplant 24 2 682 685
31. GK Abou-Alfa L Schwartz S Ricci D Amadori A Santoro A Figer J De Greve JY Douillard C Lathia B Schwartz I Taylor M Moscovici LB Saltz 2006 Phase II study of sorafenib in patients with advanced hepatocellular carcinoma J Clin Oncol 24 26 4293 4300 (Pubitemid 46630787)
32. JM Llovet S Ricci V Mazzaferro P Hilgard E Gane JF Blanc AC de Oliveira A Santoro JL Raoul A Forner M Schwartz C Porta S Zeuzem L Bolondi TF Greten PR Galle JF Seitz I Borbath D Häussinger T Giannaris M Shan M Moscovici D Voliotis J Bruix SHARP Investigators Study Group 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 4 378 390
33. KN Chi SL Ellard SJ Hotte P Czaykowski M Moore JD Ruether AJ Schell S Taylor C Hansen I Gauthier W Walsh L Seymour 2008 A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer Ann Oncol 19 4 746 751
34. WL Dahut C Scripture E Posadas L Jain JL Gulley PM Arlen JJ Wright Y Yu L Cao SM Steinberg JB Aragon-Ching J Venitz E Jones CC Chen WD Figg 2008 A phase II clinical trial of sorafenib in androgen-independent prostate cancer Clin Cancer Res 14 1 209 214
35. B Escudier T Eisen WM Stadler C Szczylik S Oudard M Siebels S Negrier C Chevreau E Solska AA Desai F Rolland T Demkow TE Hutson M Gore S Freeman B Schwartz M Shan R Simantov RM Bukowski TARGET Study Group 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2 125 134 (Pubitemid 46089673)
36. H Izzedine I Brocheriou O Rixe G Deray 2007 Interstitial nephritis in a patient taking sorafenib Nephrol Dial Transplant 22 8 2411 (Pubitemid 47244737)
37. NS Azad EM Posadas VE Kwitkowski SM Steinberg L Jain CM Annunziata L Minasian G Sarosy HL Kotz A Premkumar L Cao D McNally C Chow HX Chen JJ Wright WD Figg EC Kohn 2008 Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity J Clin Oncol 26 22 3709 3714
38. VH Haase 2006 Hypoxia-inducible factors in the kidney Am J Physiol Renal Physiol 291 2 F271 F281
39. CJ Schofield PJ Ratcliffe 2004 Oxygen sensing by HIF hydroxylases Nat Rev Mol Cell Biol 5 5 343 354 (Pubitemid 38579472)
40. WM Bernhardt R Schmitt C Rosenberger PM Münchenhagen HJ Gröne U Frei C Warnecke S Bachmann MS Wiesener C Willam KU Eckardt 2006 Expression of hypoxia-inducible transcription factors in developing human and rat kidneys Kidney Int 69 1 114 122 (Pubitemid 43117746)
41. LM Greenberger ID Horak D Filpula P Sapra M Westergaard HF Frydenlund C Albaek H Schroder H Orum 2008 A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth Mol Cancer Ther 7 11 3598 3608
42. Lewis N, Cohen RB, Nishida Y et al (2008) Phase I, pharmacokinetic (PK), dose-escalation study of EZN 2968, a novel hypoxia-inducible factor-1alpha RNA antagonist, administered weekly in patients with solid tumors. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva: abstract #398
43. SJ Bray 2006 Notch signalling: a simple pathway becomes complex Nat Rev Mol Cell Biol 7 9 678 689 (Pubitemid 44268213)
44. RC Sainson AL Harris 2008 Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies Angiogenesis 11 1 41 51
45. I Noguera-Troise C Daly NJ Papadopoulos S Coetzee P Boland NW Gale HC Lin GD Yancopoulos G Thurston 2006 Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis Nature 444 7122 1032 1037 (Pubitemid 46018516)
46. MR Pollak 2008 Focal segmental glomerulosclerosis: recent advances Curr Opin Nephrol Hypertens 17 2 138 142
47. HT Cheng M Kim MT Valerius K Surendran K Schuster-Gossler A Gossler AP McMahon R Kopan 2007 Notch2, but not Notch1, is required for proximal fate acquisition in the mammalian nephron Development 134 4 801 811 (Pubitemid 46437921)
48. T Niranjan B Bielesz A Gruenwald MP Ponda JB Kopp DB Thomas K Susztak 2008 The Notch pathway in podocytes plays a role in the development of glomerular disease Nat Med 14 3 290 298
49. M Kretzler L Allred 2008 Notch inhibition reverses kidney failure Nat Med 14 3 246 247
50. AL Schechter MC Hung L Vaidyanathan RA Weinberg TL Yang-Feng U Francke A Ullrich L Coussens 1985 The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor Science 229 4717 976 978 (Pubitemid 16248489)
51. AW Burgess 2008 EGFR family: structure physiology signaling and therapeutic targets Growth Factors 26 5 263 274
52. EA Perez M Baweja 2008 HER2-positive breast cancer: current treatment strategies Cancer Invest 26 6 545 552
53. I Arany JK Megyesi H Kaneto S Tanaka RL Safirstein 2004 Activation of ERK or inhibition of JNK ameliorates H(2)O(2) cytotoxicity in mouse renal proximal tubule cells Kidney Int 4 1231 1239 (Pubitemid 38406961)
54. I Arany JK Megyesi JE Reusch RL Safirstein 2005 CREB mediates ERK-induced survival of mouse renal tubular cells after oxidant stress Kidney Int 68 4 1573 1582 (Pubitemid 43169902)
55. FA Shepherd J Rodrigues Pereira T Ciuleanu EH Tan V Hirsh S Thongprasert D Campos S Maoleekoonpiroj M Smylie R Martins M van Kooten M Dediu B Findlay D Tu D Johnston A Bezjak G Clark P Santabárbara L Seymour National Cancer Institute of Canada Clinical Trials Group 2005 Erlotinib in previously treated non-small cell lung cancer N Engl J Med 353 2 123 132 (Pubitemid 41058344)
56. AA Miller DJ Murry K Owzar DR Hollis LD Lewis HL Kindler JL Marshall MA Villalona-Calero MJ Edelman RJ Hohl SM Lichtman MJ Ratain 2007 Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101 J Clin Oncol 25 21 3055 3060 (Pubitemid 47218052)
57. K Masutani K Fujisaki H Maeda J Toyonaga I Inoshima K Takayama R Katafuchi H Hirakata K Tsuruya M Iida 2008 Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib Clin Exp Nephrol 12 5 398 402
58. R Kumasaka N Nakamura K Shirato H Osawa S Takanashi Y Hasegawa H Yamabe M Nakamura M Tamura K Okumura 2004 Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy J Clin Oncol 22 12 2504 2505
59. A Lautrette S Li R Alili SW Sunnarborg M Burtin DC Lee G Friedlander F Terzi 2005 Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach Nat Med 11 8 867 874 (Pubitemid 41161119)
60. DK Patel 2008 Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer Pharmacotherapy 28 11 Pt 2 31S 41S
61. C Giro B Berger E Bölke IF Ciernik F Duprez L Locati S Maillard M Ozsahin R Pfeffer AG Robertson JA Langendijk W Budach 2009 High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes Radiother Oncol 90 2 166 171
62. DL Nielsen M Andersson C Kamby 2009 HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors Cancer Treat Rev 35 2 121 136
63. K Nakanishi W Sweeney Jr ED Avner 2001 Segment-specific c-ErbB2 expression in human autosomal recessive polycystic kidney disease J Am Soc Nephrol 12 2 379 384 (Pubitemid 32116382)
64. O Mir P Berveiller S Ropert F Goffinet G Pons JM Treluyer F Goldwasser 2008 Emerging therapeutic options for breast cancer chemotherapy during pregnancy Ann Oncol 19 4 607 613
65. PJ Medina S Goodin 2008 Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases Clin Ther 30 8 1426 1447
66. PA Cassier A Dufresne S Arifi H El Sayadi I Labidi I Ray-Coquard S Tabone P Méeus D Ranchère MP Sunyach AV Decouvelaere L Alberti JY Blay 2008 Imatinib mesilate for the treatment of gastrointestinal stromal tumour Expert Opin Pharmacother 9 7 1211 1222
67. BJ Druker M Talpaz DJ Resta B Peng E Buchdunger JM Ford NB Lydon H Kantarjian R Capdeville S Ohno-Jones CL Sawyers 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 14 1031 1037 (Pubitemid 32267972)
68. P Chevallier M Hunault-Berger F Larosa C Dauriac R Garand JL Harousseau 2008 A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial Leuk Res 10.1016/j.leukres.2008.09.030
69. H François P Coppo JP Hayman B Fouqueray B Mougenot P Ronco 2008 Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss Am J Kidney Dis 51 2 298 301
70. M Pou N Saval M Vera A Saurina M Solé F Cervantes A Botey 2003 Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia Leuk Lymphoma 44 7 1239 1241 (Pubitemid 36609120)
71. JR Foringer RR Verani VM Tjia KW Finkel JA Samuels JS Guntupalli 2005 Acute renal failure secondary to imatinib mesylate treatment in prostate cancer Ann Pharmacother 39 12 2136 2138 (Pubitemid 41745965)
72. MW Deininger 2008 Nilotinib Clin Cancer Res 14 13 4027 4031
73. J Cortes DW Kim E Raffoux G Martinelli E Ritchie L Roy S Coutre S Corm N Hamerschlak JL Tang A Hochhaus HJ Khoury TH Brümmendorf M Michallet G Rege-Cambrin C Gambacorti-Passerini JP Radich T Ernst C Zhu JM Van Tornout M Talpaz 2008 Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase Leukemia 22 12 2176 2183
74. PM Comoglio S Giordano L Trusolino 2008 Drug development of MET inhibitors: targeting oncogene addiction and expedience Nat Rev Drug Discov 7 6 504 516
75. Y Liu J Yang 2006 Hepatocyte growth factor: new arsenal in the fights against renal fibrosis? Kidney Int 70 2 238 240 (Pubitemid 44086571)
76. R Srinivasan TK Choueiri U Vaishampayan JE Rosenberg MN Stein T Logan RM Bukowski T Mueller HN Keer WM Linehan 2008 A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC) J Clin Oncol 26 May 20 suppl 5103 abstract
77. AS Levey JP Bosch JB Lewis T Greene N Rogers D Roth 1999 A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 6 461 470
78. V Launay-Vacher S Oudard N Janus J Gligorov X Pourrat O Rixe JF Morere P Beuzeboc G Deray 2007 Renal insufficiency and cancer medications (IRMA) study group. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study Cancer 110 6 1376 1384
79. PE Kintzel 2001 Anticancer drug-induced kidney disorders Drug Saf 24 1 19 38
80. MW Karaman S Herrgard DK Treiber P Gallant CE Atteridge BT Campbell KW Chan P Ciceri MI Davis PT Edeen R Faraoni M Floyd JP Hunt DJ Lockhart ZV Milanov MJ Morrison G Pallares HK Patel S Pritchard LM Wodicka PP Zarrinkar 2008 A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 1 127 132
81. H Izzedine I Brocheriou G Deray O Rixe 2007 Thrombotic microangiopathy and anti-VEGF agents Nephrol Dial Transplant 22 5 1481 1482 (Pubitemid 47072247)
82. M Scartozzi E Galizia S Chiorrini R Giampieri R Berardi C Ierantoni S Cascinu 2009 Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab Ann Oncol 20 2 227 230
83. O Rixe B Billemont H Izzedine 2007 Hypertension as a predictive factor of Sunitinib activity Ann Oncol 18 6 1117 (Pubitemid 47050505)
84. BI Rini JH Schiller JP Fruehauf EE Cohen JC Tarazi B Rosbrook AD Ricart AJ Olszanski S Kim J Spano 2008 Association of diastolic blood pressure (dBP) ≥90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736) J Clin Oncol 26 May 20 suppl 3543 abstract
85. KD Miller LI Chap FA Holmes MA Cobleigh PK Marcom L Fehrenbacher M Dickler BA Overmoyer JD Reimann AP Sing V Langmuir HS Rugo 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 4 792 799 (Pubitemid 46224178)
86. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NE Davidson 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 26 2666 2676
87. MN Dickler HS Rugo CA Eberle E Brogi JF Caravelli KS Panageas J Boyd B Yeh DE Lake CT Dang TA Gilewski JF Bromberg AD Seidman GM D'Andrea MM Moasser M Melisko JW Park J Dancey L Norton CA Hudis 2008 A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer Clin Cancer Res 14 23 7878 7883
88. S Dellapasqua F Bertolini V Bagnardi E Campagnoli E Scarano R Torrisi Y Shaked P Mancuso A Goldhirsch A Rocca E Pietri M Colleoni 2008 Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer J Clin Oncol 26 30 4899 4905
89. JC Yang L Haworth RM Sherry P Hwu DJ Schwartzentruber SL Topalian SM Steinberg HX Chen SA Rosenberg 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 5 427 434 (Pubitemid 36910021)
90. B Escudier A Pluzanska P Koralewski A Ravaud S Bracarda C Szczylik C Chevreau M Filipek B Melichar E Bajetta V Gorbunova JO Bay I Bodrogi A Jagiello-Gruszfeld N Moore AVOREN Trial investigators 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial Lancet 370 9605 2103 2111 (Pubitemid 350296300)
91. BI Rini S Halabi JE Rosenberg WM Stadler DA Vaena SS Ou L Archer JN Atkins J Picus P Czaykowski J Dutcher EJ Small 2008 Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 33 5422 5428
92. RM Bukowski 2008 Randomized trial of bevacizumab in advanced renal cell carcinoma Curr Oncol Rep 10 2 99 100
93. DH Johnson L Fehrenbacher WF Novotny RS Herbst JJ Nemunaitis DM Jablons CJ Langer RF DeVore 3rd J Gaudreault LA Damico E Holmgren F Kabbinavar 2004 Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 11 2184 2191 (Pubitemid 41095154)
94. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati R Lilenbaum DH Johnson 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 24 2542 2550 (Pubitemid 44917502)
95. RS Herbst DH Johnson E Mininberg DP Carbone T Henderson ES Kim G Blumenschein Jr JJ Lee DD Liu MT Truong WK Hong H Tran A Tsao D Xie DA Ramies R Mass S Seshagiri DA Eberhard SK Kelley A Sandler 2005 Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 11 2544 2555
96. RS Herbst VJ O'Neill L Fehrenbacher CP Belani PD Bonomi L Hart O Melnyk D Ramies M Lin A Sandler 2007 Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer J Clin Oncol 25 30 4743 4750 (Pubitemid 350086476)
97. HS Hochster LL Hart RK Ramanathan BH Childs JD Hainsworth AL Cohn L Wong L Fehrenbacher Y Abubakr MW Saif L Schwartzberg E Hedrick 2008 Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study J Clin Oncol 26 21 3523 3529
98. LB Saltz S Clarke E Diaz-Rubio W Scheithauer A Figer R Wong S Koski M Lichinitser TS Yang F Rivera F Couture F Sirzen J Cassidy 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 12 2013 2019
99. J Tol M Koopman CJ Rodenburg A Cats GJ Creemers JG Schrama FL Erdkamp AH Vos L Mol NF Antonini CJ Punt 2008 A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the dutch colorectal cancer group (DCCG). an interim analysis of toxicity Ann Oncol 19 4 734 738
100. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2335 2342 (Pubitemid 38702844)